The Singapore Chinese Health Study

在这份提案中，我们提出了继续为新加坡华人健康提供基础设施支持的理由。 这项研究于20世纪90年代初在新加坡招募了63,257名中国男性和女性。 需要基础设施支持来维持和加强针对这种独特癌症的既定基础设施 流行病学队列，重复收集问卷调查数据和来自队列的生物样本 参与者到目前为止，大约20%的队列参与者被诊断患有癌症;超过20%的人被诊断患有癌症。 5,500名癌症患者提供了癌症诊断前收集的基线生物样本。未来5 新加坡华人健康研究将增加4,000个新的癌症病例，其中2,000个 与现有的基线生物标本，将提供独特的资源，为发展生物标志物为基础的 癌症流行病学研究。随着对整个队列的全基因组基因分型的完成， 外泌体基因序列在未来两年内，这一癌症流行病学队列也将提供独特的 研究基因-环境相互作用对癌症风险的影响。一些新奇的发现 为我们在美国进行化学预防试验提供了强有力的理由。 人口数量。利用独特和先进的电子医疗记录和疾病登记系统， 我们几乎完全保留了参与者;只有不到0.1%的原始队列参与者 已知的是我们失去了监测和跟踪癌症发病率，癌症死亡率，以及许多其他慢性 由于他们从新加坡迁移出来而感染的疾病。在未来五年的研究期间，我们建议：（1） 继续随访所有存活参与者的癌症发病率、癌症死亡率、死因特异性死亡， 和其他非癌症健康结果;（2）维护和更新生物储存库;（3）更新和整合 来自随访访谈、疾病结局评估、动态生物储存库的所有数据元素 （4）将新的库存和新的实验室测量数据输入研究项目的主队列数据库; 支持和加强创新的癌症流行病学研究，作为特定群体的辅助项目， 群组联盟项目。我们预计，这一亚洲群体的现有资源将变得均衡， 在接下来的五年里，年轻的参与者，特别是那些提供了 基线生物样本，将进入癌症发病率最高的年龄，从而增加 癌症病例的数量，为疾病前生物标志物为基础的研究项目提供资源。

In this proposal we provide a rationale for continued infrastructure support for the Singapore Chinese Health Study that enrolled 63,257 Chinese men and women at baseline in the early 1990s in Singapore. Infrastructure support is needed to maintain and enhance the established infrastructure for this unique cancer epidemiology cohort with repeated collections of questionnaire survey data and biological samples from cohort participants. To date, approximately 20% of the cohort participants were diagnosed with cancers; more than 5,500 cancer patients provided baseline biological samples collected before cancer diagnosis. In the next 5 years the Singapore Chinese Health Study will accrue an additional 4,000 new cancer cases, 2,000 of them with available baseline biospecimens that will provide unique resources for development of biomarker-based cancer epidemiological studies. With the completion of the genome-wide genotyping on the entire cohort and exosome gene sequence in the next two years, this cancer epidemiology cohort will also provide unique opportunity for examining the gene-environmental interaction on risk of cancer. Some of the novel findings from this Asian population has provided a strong rationale for us to conduct chemoprevention trials in U.S. populations. Leveraging the unique and advanced system of electronic medical records and disease registries, we have virtually full retention of the participants; only less than 0.1% of the original cohort participants were known to be lost to our monitoring and tracking cancer incidence, cancer mortality, and many other chronic diseases due to their migration out of Singapore. During the next 5-year study period, we propose to: (1) continue to follow up for all surviving participants for cancer incidence, cancer mortality, cause-specific death, and other non-cancer health outcomes; (2) maintain and update the biorepositories; (3) update and integrate all data elements from follow-up interviews, assessment of disease outcomes, dynamic biorepository inventories, and new laboratory measurements into the master cohort database for research projects; and (4) support and enhance innovative cancer epidemiological studies as cohort-specific ancillary projects and large cohort consortium projects. We anticipate that the established resources of this Asian cohort will become even more scientifically valuable over the next five years as the young participants, especially those who provided baseline biological samples, will enter into the age of maximal cancer incidence, thereby increasing the number of cancer cases that provide resources for pre-disease biomarker-based research projects.